Cyberknife is a brand name for SBRT.
One nice thing about being on a trial, whichever trial arm you end up on, is that you tend to be monitored more frequently and in more detail than normal. That can pick up issues that might otherwise have been missed. OTOH, that might mean attending more appointments, and having blood tests for the trial which need to be within a specific time window, and a week later, having the same test again for your consultant.
If you had conventional IMRT, do you know what would be treated? I was a high risk patient in a similar way to you (T3a rather than T3b). Although no spread to seminal vesicles or pelvic lymph nodes, they were also treated at half dose on the basis that they are where micro-mets are most likely to exist outside the prostate. (Chance of micro-mets increases with higher risk diagnosis.) I liked the idea of a softer focus dosing target of IMRT, with a chance of mopping up any other micro-mets nearby. Yes, this increased the chance of side effects, and I do have some occasional painless minor rectal bleeding (which has no impact on my quality of life).
I just don't know SBRT in the same detail, but I wonder if it would provide the same protection against micro-mets? Fine targeting is great for limiting side effects in a low risk contained cancer, but I can't help feeling it might increase the chance of micro-mets escaping treatment in a high risk cancer. I would want to ask about this, and ask exactly what they would be targeting if you had SBRT and how that would compare with targeting using IMRT.
Edited by member 28 Dec 2020 at 20:32
| Reason: Not specified